Plasma glucagon responses (Figure 3B) increased in both ZT-01 treated groups (T2D and HFF controls) peaking at t = 30 min, with significantly higher levels (p < 0.05) observed in the HFF-ZT-01 treatment group (201.7 ± 32.4 pg/mL) compared to HFF vehicle group (14.7 ± 14.7 pg/mL). The gene discussed is GCG; the disease is type 2 diabetes mellitus.